Cargando…
Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder
Long-acting buprenorphine formulations have been recently marketed for the Opioid Agonist Treatment (OAT) of opioid use disorder (OUD) associated with medical, social, and psychological support. Their duration of action ranges from one week up to 6 months. The non-medical use of opioids is increasin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488107/ https://www.ncbi.nlm.nih.gov/pubmed/37685642 http://dx.doi.org/10.3390/jcm12175575 |